how long can tirzepatide be left out to Leave Before Injection Tirzepatide Dosing - A Patient

J Diabetes Investig (2015) 6(5):495507

Wegovy for subcutaneous (SC) administration is undergoing a Priority Review from the FDA for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), a fatty liver condition tied to obesity and T2DM

This medication must be combined with lifestyle changes for optimal results

Both sexes were well represented, and subjects covered several races and different ethnicities and were recruited from many countries

Most active users also expect short-term treatment: 69% have used GLP-1 weight loss medications for fewer than two years, and over half plan to stop within two more years